Our understanding of quality in healthcare—how we talk about it and how we measure it—has evolved over time. However, the goal has remained the same: improving the health of people living with HIV. This means constantly challenging ourselves to do better. In essence, do quality improvement (QI) better.
The prevailing opinion among experts regarding the optimal CD4 T-cell count at which to start patients on antiretroviral therapy (ART) has shifted several times during the evolution of HIV treatment. These shifts reflect attempts to strike a balance between preventing HIV-associated illness and death and minimizing medication-related toxicity. Two large randomized controlled clinical trials, the START study and the TEMPRANO study, now demonstrate that earlier treatment with ART is most beneficial to boost immune recovery and prevent clinical events.
National Quality Center (NQC) has completed its evaluation of the in+care Campaign -- the largest HIV quality improvement initiative carried out at the national level. We are pleased to announce that the Campaign demonstrated significant improvements in national retention and viral load suppression (VLS) performance.
Annual meetings of the Centers for Disease Control and Prevention (CDC)-sponsored Elimination of Mother-to-Child Transmission of HIV (EMCT) Stakeholders Group and the Expert Panel on Reproductive Health and Preconception Care for Persons Living with HIV, held at the Washington, D.C. headquarters of the American College of Obstetrics and Gynecology (ACOG) the week of May 25th, 2015, provided an exciting and energizing opportunity to discuss challenging clinical and policy issues.
When incorporating best practices and guidelines for HIV care, clinicians must take into account their clients’ mental health and substance use needs. Approximately 30- 50% of people living with HIV/AIDS have current or past severe to moderate depression. At its highest estimate, that’s more than double the prevalence of the general population.
A critical shortage of practitioners who treat HIV/AIDS patients in the United States is on the horizon, according to research by the American Academy of HIV Medicine (AAHIVM), which warns that more than 32 percent of today’s HIV clinicians will stop providing that care over the next 10 years. Nearly one-third of today’s workforce will retire leaving a shortage unless new practitioners can be encouraged to replace them. The current HIV workforce is largely composed of medical providers who entered the field more than 20 years ago.
Imagine you are sitting down with a dear friend that you haven’t seen in years because he ran away from an unloving, unsupportive home, from a town where he was different, picked on, and knew he could never be safe - at least that is how he felt, - to a place where he would find love, and the supportive family he so dearly wanted. He discloses that he is gay and living with HIV infection. He says not to worry, that it’s ok, and then he says, “There’s more.” You feel your heart beat faster and time suspends.
Technology is great…when it works. This phrase comes to mind every time technology is supposed to enhance an experience and a malfunction causes that experience to cease. We know that technology should have the capacity to transform our lives, including our lives as HIV care providers. But in order for it to do so, it has to work. It has to be usable (i.e. easy, reliable, and fast). While iPad Minis have been on the market for several years now, a review of the literature yielded no current studies to examine their usability or effectiveness in clinical use.
How many of you are currently reading this blog on your phones? Wait! Don’t answer that. Just the fact that you are reading this and not playing Bejeweled means we are off to a great start. However, if you are using your cell phone to access the internet, you aren’t alone. As of May 2013, 85% of U.S. adults are online, 91% have a cell phone and 56% have a smartphone. Along with increased smartphone ownership, the use of mobile phone applications or ‘apps’ is on the rise.